Overview

A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

Status:
Recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

The objective of this clinical study is to evaluate the efficacy and safety by comparing BR1017A+BR1017B treatment group to BR1017A treatment group and BR1017B treatment group respectively at Week 8 in essential hypertension patients with primary hypercholesterolemia

Phase:

Phase 3

Details

Lead Sponsor:

Boryung Pharmaceutical Co., Ltd

Treatments:

Atorvastatin
Ezetimibe